Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7475 plus nivolumab and gemcitabine + nab-paclitaxel for first-line metastatic pancreatic cancer
jRCT2031230429Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-7475 in pancreatic cancer (PC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Dec 2023; status: active, not recruiting.
02
Drugs
ONO-7475
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031230429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230429.